{"url":"https://journals.lww.com/ccmjournal/abstract/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx","title":"Enteral Beats IV Phosphate on Cost and Waste in ICU Trial","domain":"journals.lww.com","imageUrl":"https://images.pexels.com/photos/34642911/pexels-photo-34642911.jpeg?auto=compress&cs=tinysrgb&h=650&w=940","pexelsSearchTerm":"ICU nurse administering phosphate","category":"Nature","language":"en","slug":"5d380598","id":"5d380598-6fc0-49fe-98f0-ff3e7dd4abdf","description":"Researchers ran a randomized trial in ICU patients with mild to moderate hypophosphatemia to test if enteral phosphate works as well as IV phosphate.","summary":"## TL;DR\n- Researchers ran a randomized trial in ICU patients with mild to moderate hypophosphatemia to test if enteral phosphate works as well as IV phosphate.\n- Enteral raised serum phosphate to **0.89 mmol/L** at 24 hours, noninferior to IV's **0.82 mmol/L** (difference **0.07 mmol/L**, 95% CI –0.02 to 0.17 within 0.2 mmol/L margin).\n- Enteral cut costs **10-fold** to **$3.7** per patient, slashed waste by **209 g**, and dropped CO₂ emissions **60-fold** versus IV.\n\n## The story at a glance\nThis trial compared enteral versus IV phosphate replacement in 131 ICU patients at Royal Melbourne Hospital with serum phosphate levels of **0.3-0.75 mmol/L**. Lead authors Chinh D. Nguyen and Adam M. Deane from University of Melbourne ran the study from April to July 2022 using an electronic medical record system for randomization. It shows enteral replacement matches IV on phosphate correction but adds big gains in cost and waste. Hypophosphatemia is common in critical illness and often treated with IV phosphate despite its fluid load and packaging.\n\n## Key points\n- **Design**: Prospective, single-center, parallel-group noninferiority trial in a 42-bed trauma, medical, and surgical ICU; modified intention-to-treat analysis of **131 patients**.\n- **Patients**: Critically ill adults with serum phosphate **0.3-0.75 mmol/L** (mild-moderate hypophosphatemia); baseline levels similar between groups.[[1]](https://journals.lww.com/ccmjournal/fulltext/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx)[[2]](https://journals.lww.com/ccmjournal/abstract/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx)\n- **Interventions**: Enteral phosphate (e.g., effervescent tablets) or IV phosphate (delivering ~20 mmol in ~**408 mL** solvent fluid, SD 372 mL).\n- **Primary outcome**: Serum phosphate at **24 hours**; enteral **0.89 mmol/L** (SD 0.24) vs. IV **0.82 mmol/L** (SD 0.28); difference **0.07 mmol/L** (95% CI, –0.02 to 0.17), meeting noninferiority margin of **0.2 mmol/L**.[[3]](https://pubmed.ncbi.nlm.nih.gov/38537225)\n- **Cost**: Enteral **$3.7** (SD $4.0) vs. IV **$37.7** (SD $31.4) per patient; savings **$34** (95% CI, $26.3-$41.7).\n- **Waste**: Enteral **7.7 g** (SD 8.3 g) vs. IV **217 g** (SD 169 g); reduction **209 g** (95% CI, 168-250 g).\n- **Environment**: Enteral ~**2 g** phosphate produced **14.2 g CO₂**; equivalent IV produced **843 g CO₂ equivalents** (~**60-fold** more).\n\n## Details and context\nHypophosphatemia affects many ICU patients due to shifts from refeeding, respiratory alkalosis, or drugs like insulin. IV replacement is standard but adds fluid volume (risking overload in fluid-restricted patients) and generates plastic waste from bags/syringes.\n\nThe trial used electronic prompts for seamless delivery, limiting it to one center over ~2.5 months. No safety issues like hyperphosphatemia or GI intolerance were highlighted. Enteral avoids ~**400 mL** extra IV fluid per dose, which matters in sepsis or heart failure cases.\n\nSecondary measures confirm practical benefits without biochemical harm; CO₂ estimates use life-cycle analysis for production/disposal.\n\n## Key quotes\n> \"Enteral phosphate replacement in ICU is noninferior to IV replacement at a margin of 0.2 mmol/L but leads to a substantial reduction in cost and waste.\"[[1]](https://journals.lww.com/ccmjournal/fulltext/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx)\n\n## Why it matters\nHypophosphatemia treatment shapes ICU resource use, fluid balance, and sustainability amid rising care demands. Clinicians can switch to enteral for mild-moderate cases, saving ~**$34** per patient, cutting waste by over **200 g**, and slashing emissions without losing efficacy. Watch for larger trials on severe hypophosphatemia or long-term outcomes, plus adoption in guidelines.","hashtags":["#icu","#criticalcare","#hypophosphatemia","#nutrition","#sustainability","#healthcare"],"sources":[{"url":"https://journals.lww.com/ccmjournal/abstract/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx","title":"Original article"},{"url":"https://journals.lww.com/ccmjournal/fulltext/2024/07000/a_randomized_noninferiority_trial_to_compare.7.aspx","title":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/38537225","title":""}],"viewCount":2,"publishedAt":"2026-04-08T22:12:57.203Z","createdAt":"2026-04-08T22:12:57.203Z","articlePublishedAt":null}